Fishman Jay A Ltd. MI Cuts Holdings in Zoetis Inc. (NYSE:ZTS)

Fishman Jay A Ltd. MI cut its position in Zoetis Inc. (NYSE:ZTS) by 7.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 90,194 shares of the company’s stock after selling 7,093 shares during the period. Zoetis accounts for approximately 1.4% of Fishman Jay A Ltd. MI’s investment portfolio, making the stock its 16th biggest holding. Fishman Jay A Ltd. MI’s holdings in Zoetis were worth $14,695,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of ZTS. AMF Tjanstepension AB raised its stake in Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after buying an additional 20,001 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in Zoetis by 4,582.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 1,639 shares of the company’s stock worth $320,000 after buying an additional 1,604 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH purchased a new position in Zoetis during the 3rd quarter worth approximately $127,000. Oliver Luxxe Assets LLC acquired a new stake in Zoetis during the 3rd quarter valued at approximately $206,000. Finally, Sapient Capital LLC increased its stake in shares of Zoetis by 212.7% in the third quarter. Sapient Capital LLC now owns 4,859 shares of the company’s stock worth $949,000 after acquiring an additional 3,305 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ZTS shares. Stifel Nicolaus reduced their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Piper Sandler decreased their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday. Finally, Morgan Stanley dropped their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $214.00.

Zoetis Trading Up 1.5 %

Shares of Zoetis stock opened at $174.47 on Wednesday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The firm has a market capitalization of $78.72 billion, a PE ratio of 32.80, a P/E/G ratio of 2.77 and a beta of 0.90. The firm’s 50-day moving average price is $169.16 and its 200 day moving average price is $179.15.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.15%. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.